One of my top FTSE 100 picks is down over 10%. Here’s what I’d do now

This Fool likes the look of this FTSE 100 stalwart, especially now its share price has dropped.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A top FTSE 100 share I like is the biopharmaceutical giant, AstraZeneca (LSE:AZN). Its share price value has dropped over 10% in the market crash, and I believe this is a prime opportunity to pick up shares.

AstraZeneca employs more than 60,000 people in over 100 countries. In the UK alone it directly employs over 5,000 people at five locations, including its headquarters in Cambridge. 

It has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Covid-19

Pharma companies can experience a knock on benefit from economic uncertainty. When this uncertainty is due to a health issue or pandemic, they may profit as demand for pharmaceutical goods and services usually increases. 

AstraZeneca has positioned itself to help with a potential treatment for Covid-19. It has launched its fastest ever clinical drugs trial to see whether its oncology drug Calquence could reduce the need for ventilators and the number of deaths. 

CEO Pascal Soriot confirmed the Covid-19 impact on business has been limited. This is despite fears that its fastest growing region, China, would suffer long-term effects. China seems to have curbed the virus and has even reopened Wuhan, the epicentre of the outbreak. 

Performance & the numbers

In March, AstraZeneca released its full-year results to 31 December 2019. The key highlights for me were that total revenue was up by 13%, including a 15% increase in product sales. 

Operating profit did see a 16% decrease compared the previous year but this does not concern me. The decrease was caused by higher expenses related to new drugs launches coupled with aggressive expansion into China.

Expansion into China helped sales in the region jump by 35% in 2019 alone. ‘New medicines’ made up 42% of total sales in 2019, which equates to $3.8bn. Considering these are newer drugs on the market, I think their demand and sales numbers will only continue to increase. 

Covid-19 makes it difficult for the company to provide guidance for 2020. This wasn’t a surprise to me as the extent of the pandemic is unknown. The majority of companies are taking the same stance during this turbulent time.

AstraZeneca’s share price was close to 7,840p per share in the middle of January. The market crash saw it drop to about 6,220p per share in the middle of March. At the time of writing, the share price has climbed over the 7,000p per share price mark. This shows the stalwart is mounting a recovery in a bear market. AZN also has a dividend yield of near 3%, which is an enticing factor for me.

With over $6bn spent in 2019 on R&D and a project pipeline of over 160 drugs, the company is well-positioned for continued success, I believe.

In my opinion, as well as many others, AstraZeneca is one of only a few names in the FTSE 100 to have a moat. I see nothing but an increasing share price and success longer term for the company.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower
Investing Articles

I’m on the hunt for cheap shares to buy this January! Here’s one I found

Christopher Ruane has been looking at the UK stock market to try and find shares to buy for his portfolio.…

Read more »

Investing Articles

4 SIPP mistakes I’m avoiding like the plague!

Christopher Ruane explains four errors he is trying hard to avoid in investing his SIPP, as he tries to maximise…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Up 28% in a month, I’ve been loading up on this penny share  

Our writer has been buying more of a penny share he already holds and reckons recent news could point to…

Read more »

Investing Articles

How to aim for a reliable 6% dividend yield when picking stocks

Mark Hartley outlines his strategy to identify top-quality stocks with high dividend yields and strong fundamentals for consistent income.

Read more »

Investing Articles

Investing £20,000 in this FTSE 250 stock today could net investors £1,944 in passive income this year

After falling 11% in a week, this FTSE 250 company is set to return almost 10% of the its market…

Read more »

Investing Articles

I asked ChatGPT to name the best S&P 500 growth stock and it picked this AI powerhouse

Muhammad Cheema asked ChatGPT to pick its top S&P 500 growth stock. He was disappointed with its response, which missed…

Read more »

Investing Articles

£10k in savings? Here’s how an investor could use that to target £420 of passive income a month

Harvey Jones shows how it’s possible to build a high and rising passive income from a portfolio of FTSE 100…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Investing £5k in each of these 3 FTSE stocks in January 2023 would have created a £55k ISA!

Our writer highlights a trio of UK shares that have absolutely rocketed recently, boosting any ISA that held them along…

Read more »